KR20240089224A - 4-원 융합 고리형 화합물 및 이의 제조방법 및 용도 - Google Patents
4-원 융합 고리형 화합물 및 이의 제조방법 및 용도 Download PDFInfo
- Publication number
- KR20240089224A KR20240089224A KR1020247014535A KR20247014535A KR20240089224A KR 20240089224 A KR20240089224 A KR 20240089224A KR 1020247014535 A KR1020247014535 A KR 1020247014535A KR 20247014535 A KR20247014535 A KR 20247014535A KR 20240089224 A KR20240089224 A KR 20240089224A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- alkyl
- pharmaceutically acceptable
- acceptable salt
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/22—Eight-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111161691.X | 2021-09-30 | ||
| CN202111161691 | 2021-09-30 | ||
| PCT/CN2022/122536 WO2023051681A1 (zh) | 2021-09-30 | 2022-09-29 | 四元稠环类化合物及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240089224A true KR20240089224A (ko) | 2024-06-20 |
Family
ID=85781355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247014535A Pending KR20240089224A (ko) | 2021-09-30 | 2022-09-29 | 4-원 융합 고리형 화합물 및 이의 제조방법 및 용도 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240400582A1 (https=) |
| EP (1) | EP4410779A4 (https=) |
| JP (1) | JP2024534707A (https=) |
| KR (1) | KR20240089224A (https=) |
| CN (1) | CN118139849A (https=) |
| AU (1) | AU2022355393A1 (https=) |
| CA (1) | CA3234312A1 (https=) |
| IL (1) | IL311791A (https=) |
| MX (1) | MX2024004025A (https=) |
| TW (1) | TW202330547A (https=) |
| WO (1) | WO2023051681A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ773110A (en) | 2018-09-18 | 2024-11-29 | Terns Inc | Compounds for treating certain leukemias |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0003476D0 (sv) * | 2000-09-28 | 2000-09-28 | Astrazeneca Ab | Compounds |
| CN103113355B (zh) * | 2013-02-27 | 2014-08-13 | 无锡爱内特生物科技有限公司 | 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用 |
| CN109790144A (zh) * | 2016-04-29 | 2019-05-21 | 爱仕达生物技术有限责任公司 | 新型杂环化合物作为酪氨酸激酶bcr-abl抑制剂 |
| US11649218B2 (en) * | 2018-03-09 | 2023-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same |
-
2022
- 2022-09-29 EP EP22875063.4A patent/EP4410779A4/en active Pending
- 2022-09-29 MX MX2024004025A patent/MX2024004025A/es unknown
- 2022-09-29 WO PCT/CN2022/122536 patent/WO2023051681A1/zh not_active Ceased
- 2022-09-29 US US18/697,312 patent/US20240400582A1/en active Pending
- 2022-09-29 KR KR1020247014535A patent/KR20240089224A/ko active Pending
- 2022-09-29 IL IL311791A patent/IL311791A/en unknown
- 2022-09-29 CA CA3234312A patent/CA3234312A1/en active Pending
- 2022-09-29 CN CN202280064600.7A patent/CN118139849A/zh active Pending
- 2022-09-29 AU AU2022355393A patent/AU2022355393A1/en active Pending
- 2022-09-29 JP JP2024543428A patent/JP2024534707A/ja active Pending
- 2022-09-30 TW TW111137341A patent/TW202330547A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024004025A (es) | 2024-05-31 |
| EP4410779A4 (en) | 2025-07-30 |
| TW202330547A (zh) | 2023-08-01 |
| CN118139849A (zh) | 2024-06-04 |
| IL311791A (en) | 2024-05-01 |
| WO2023051681A1 (zh) | 2023-04-06 |
| AU2022355393A1 (en) | 2024-05-09 |
| CA3234312A1 (en) | 2023-04-06 |
| US20240400582A1 (en) | 2024-12-05 |
| JP2024534707A (ja) | 2024-09-20 |
| EP4410779A1 (en) | 2024-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI765908B (zh) | 苯並咪唑類化合物激酶抑制劑及其製備方法和應用 | |
| CN113214287B (zh) | Hpk1抑制剂及其使用方法 | |
| CN113179640B (zh) | 含氮多环类衍生物抑制剂、其制备方法和应用 | |
| AU2013227139B2 (en) | Nitrogen-containing aromatic heterocyclic compound | |
| JP5976826B2 (ja) | Ｂｔｋ活性阻害剤としての８−フルオロフタラジン−１（２ｈ）−オン化合物 | |
| CN113348170B (zh) | 联苯类衍生物抑制剂、其制备方法和应用 | |
| TW202108582A (zh) | 含二並環類衍生物抑制劑、其製備方法和應用 | |
| TW202317564A (zh) | Cdk2抑制劑及其製備方法和用途 | |
| ES2920702T3 (es) | Compuestos de heteroarilo como inhibidores de cinasas | |
| KR20240051987A (ko) | 질소-함유 헤테로사이클릭 유도체 억제제, 이의 제조 방법 및 이의 용도 | |
| KR20190141215A (ko) | N-(아자릴)시클로락탐-1-카르복사미드 유도체 및 합성법과 그 용법 | |
| BR112015020772B1 (pt) | Compostos de pirimidina e piridina e seu uso | |
| EA020777B1 (ru) | 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus | |
| JP2022534063A (ja) | インドール誘導体含有阻害剤、そのための調製方法及びその用途 | |
| KR20230107271A (ko) | 이환식 유도체를 포함하는 억제제 유리염기의 결정형, 이의 제조방법 및 용도 | |
| TW202444385A (zh) | Ｅｇｆｒ降解劑、其藥物組成物及其用途 | |
| KR20240089224A (ko) | 4-원 융합 고리형 화합물 및 이의 제조방법 및 용도 | |
| WO2022002243A1 (zh) | 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| TW202136259A (zh) | 聯苯類衍生物抑制劑及其製備方法和應用 | |
| CN120535516A (zh) | 一种POLθ抑制剂及其用途 | |
| HK40049641A (en) | Biphenyl derivative inhibitor, preparation method therefor and use | |
| HK40051502A (en) | Nitrogen-containing polycyclic derivative inhibitor, preparation method therefor and application thereof | |
| HK40003421B (en) | Benzimidazole compound kinase inhibitor, preparation method therefor and application thereof | |
| HK40003421A (en) | Benzimidazole compound kinase inhibitor, preparation method therefor and application thereof | |
| HK1261495A1 (en) | 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |